We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
ISCO and TAP Enter into Strategic Alliance to Automate Cornea Tissue Production
News

ISCO and TAP Enter into Strategic Alliance to Automate Cornea Tissue Production

ISCO and TAP Enter into Strategic Alliance to Automate Cornea Tissue Production
News

ISCO and TAP Enter into Strategic Alliance to Automate Cornea Tissue Production

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "ISCO and TAP Enter into Strategic Alliance to Automate Cornea Tissue Production"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

International Stem Cell Corporation (ISCO) has announced that it had entered into a strategic alliance with The Automation Partnership (TAP), to automate and scale up the production of stem cell-derived human corneal tissue.

The alliance has been formed to create instrumentation for ISCO and its partners and affiliates to produce development and commercial volumes of donor tissue for cornea transplantation and to reduce the use of animals and animal eyes in safety testing of drugs, chemicals and consumer products.

Cornea-related loss or reduction of vision can be caused by physical injury, infections and degenerative diseases. In cases where cornea replacement is indicated, current medical practice typically involves a one-two hour outpatient procedure under local anesthesia using full or partial corneas from healthy human cadavers. 10 million people worldwide are candidates for such treatment, primarily in Asia and Europe where there is significant quantitative and qualitative shortage of human cornea donation.

Global efforts are underway to transition from the use of live animals and excised animal eyes to test drugs, chemicals and consumer products. For example, Europe's Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH) estimates a need to spend €270M and use 160,000 animals for eye safety testing alone to catch up with the back-log of insufficiently tested agents.

In the US, the National Institutes of Health (NIH) and the Environmental Protection Agency (EPA) have launched a five-year program dedicated to finding new, non-animal technologies for toxicity testing of chemical compounds.
Advertisement